SDZ B 3243
Latest Information Update: 26 Jul 2001
At a glance
- Originator Novartis
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Leukaemia
Most Recent Events
- 26 Jul 2001 No-Development-Reported for Leukaemia in Switzerland (Unknown route)
- 26 Oct 1992 Preclinical development for Leukaemia in Switzerland (Unknown route)